Two doses of an FDA-approved sleeping pill reduced levels of Alzheimer’s proteins in a small study of healthy volunteers led by researchers at Washington University School of Medicine in St. Louis. The study hints at the potential of sleep medications to slow or stop the progression of Alzheimer’s disease, although much more work needs to be done to confirm the viability of such an approach.
Category: Washington University School of Medicine
Bateman to receive lifetime achievement award (Links to an external site)
Bateman has been chosen to receive the honor for his groundbreaking work in Alzheimer’s research, including the development of plasma biomarkers in Alzheimer’s diagnostics. He will receive the award in October at the Clinical Trials on Alzheimer’s Disease conference in Boston.
WashU, Eisai form drug discovery collaboration (Links to an external site)
Washington University School of Medicine in St. Louis and the pharmaceutical company Eisai Co. Ltd., headquartered in Japan, have formed a research collaboration aimed at developing new treatments for Alzheimer’s disease, Parkinson’s disease and other neurodegenerative conditions. The two organizations previously have partnered on Alzheimer’s clinical trials, and the new alliance combines their complementary efforts to identify and validate biomarkers and drug targets for a range of neurodegenerative conditions, with a goal of developing new drugs for the benefit of patients worldwide.
Diagnostic marker found for deadly brain disease marked by dementia, movement problems (Links to an external site)
Sato and Horie led a team that discovered a biomarker for a rare, deadly brain disease known as corticobasal degeneration (CBD). The biomarker could accelerate efforts to develop treatments for CBD.
New center’s aim: to ID biomarkers of neurodegenerative diseases (Links to an external site)
A new center established at Washington University School of Medicine in St. Louis aims to accelerate research into biomarkers of neurodegenerative conditions such as Huntington’s and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and the so-called tauopathies, a group that includes Alzheimer’s disease along with rarer diseases such as frontotemporal dementia, corticobasal syndrome […]
Blood test for Alzheimer’s highly accurate in large, international study (Links to an external site)
“A blood test for Alzheimer’s provides a huge boost for Alzheimer’s research and diagnosis, drastically cutting the time and cost of identifying patients for clinical trials and spurring the development of new treatment options,” Bateman said. “As new drugs become available, a blood test could determine who might benefit from treatment, including those at very early stages of the disease.”
Consortium to investigate role of neurofilament light chain in neurodegenerative diseases (Links to an external site)
Clinical scientists at Washington University School of Medicine in St. Louis and University College London are collaborating with pharmaceutical companies AbbVie, Biogen, Bristol Myers Squibb and Roche to investigate the role of neurofilament light (NfL) chain in neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease and Alzheimer’s disease.
Alzheimer’s protein in blood indicates early brain changes (Links to an external site)
Two decades or more before symptoms arise, plaques of a sticky protein called amyloid begin forming in the brains of people later diagnosed with Alzheimer’s disease. Researchers at Washington University School of Medicine in St. Louis have shown that levels of a specific protein in the blood rise as amyloid plaques form in the brain. […]